MAB386
Anti-Myelin Basic Protein Antibody, a.a. 82-87
culture supernatant, clone 12, Chemicon®
Synonym(s):
MBP
Sign Into View Organizational & Contract Pricing
All Photos(4)
About This Item
UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Recommended Products
biological source
rat
Quality Level
antibody form
culture supernatant
antibody product type
primary antibodies
clone
12, monoclonal
species reactivity
human, rat, sheep, mouse, rabbit, chicken, guinea pig, bovine, all
manufacturer/tradename
Chemicon®
technique(s)
ELISA: suitable
immunocytochemistry: suitable
immunohistochemistry: suitable
radioimmunoassay: suitable
western blot: suitable
isotype
IgG2a
NCBI accession no.
UniProt accession no.
shipped in
dry ice
target post-translational modification
unmodified
Gene Information
human ... MBP(4155)
mouse ... Mbp(17196)
rat ... Mbp(24547)
General description
The two major components of CNS myelin are Myelin Basic Protein (MBP) and proteolipid protein (PLP), occuring in roughly equimolar proportions. There are many neurological disorders associated with deficiencies of myelin assembly and structure. For example Multiple Sclerosis is a human disease due to multiple factors but generally characterized by the degradation of the myelin sheath. MBP ususally refers to the 18.5 kDa isoform, which is one of the most abundant proteins of the myelin sheath of adult human and bovine CNS. Genetically, MBP is the product of differential splicing of a single mRNA transcript. In humans there are 4 isoforms, 21.5, 20.2, 18.5, and 17.2 kDa. Thus, MBP are present in multiple isoforms, part of a large family of developmentally expressed, translocatable, and highly post-translationally modifed proteins with multiple binding partners. Structurally, MBP displays a predominately unorganized form with greater than 75% in random coil. Other non-CNS related functions of myelin include insulin induction and glucagon release from pancreatic islets.
Specificity
Reacts with MBP from all species tested including human, bovine, sheep, rabbit, mouse, rat, guinea pig and chicken.
Reacts with MBP from all species tested. It reacts weakly with peptides ending in the phe 91 where the 91-92 phe-phe bond is broken. Synthetic peptide 82-99 reacts very well as does intact MBP. Mapped to the region DENPVV.
Immunogen
Bovine myelin basic protein
Epitope: a.a. 82-87
Application
Anti-Myelin Basic Protein Antibody, a.a. 82-87 is an antibody against Myelin Basic Protein for use in ELISA, IC, IH, RIA & WB.
Immunohistochemistry:
A previous lot of this antibody was used on frozen sections.
ELISA/RIA:
1:1000 dilution of a previous lot of this antibody was used in ELISA/RIA.
Western Blotting:
Identifies an 18-20kDa band in westerns.
Optimal working dilutions must be determined by end user.
A previous lot of this antibody was used on frozen sections.
ELISA/RIA:
1:1000 dilution of a previous lot of this antibody was used in ELISA/RIA.
Western Blotting:
Identifies an 18-20kDa band in westerns.
Optimal working dilutions must be determined by end user.
Research Category
Neuroscience
Neuroscience
Research Sub Category
Neuronal & Glial Markers
Neurochemistry & Neurotrophins
Neuronal & Glial Markers
Neurochemistry & Neurotrophins
Quality
Evaluated by Western Blot on Mouse brain lysates.
Western Blot Analysis:
1:500 dilution of antibody lot detected four isoforms of MBP on 10 µg of Mouse brain lysates.
Western Blot Analysis:
1:500 dilution of antibody lot detected four isoforms of MBP on 10 µg of Mouse brain lysates.
Target description
18-20 kDa
Physical form
Liquid containing 0.1% sodium azide.
Unpurified
Storage and Stability
Stable for 1 year at -20ºC from date of receipt.
Analysis Note
Control
Brain tissue
Brain tissue
Other Notes
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Legal Information
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
recommended
Product No.
Description
Pricing
Storage Class Code
12 - Non Combustible Liquids
WGK
nwg
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Customers Also Viewed
Critical role for PAR1 in kallikrein 6-mediated oligodendrogliopathy.
Burda, JE; Radulovic, M; Yoon, H; Scarisbrick, IA
Glia null
Thomas Zeis et al.
Brain : a journal of neurology, 131(Pt 1), 288-303 (2007-12-07)
Multiple sclerosis is a chronic inflammatory disease of the CNS. Although progressive axonal injury and diffuse inflammatory damage has been shown in the chronic phase of the disease, little is known about the molecular mechanisms underlying these pathological processes. In
Jane A English et al.
PloS one, 7(6), e39509-e39509 (2012-06-30)
Neuroproteomics is a powerful platform for targeted and hypothesis driven research, providing comprehensive insights into cellular and sub-cellular disease states, Gene × Environmental effects, and cellular response to medication effects in human, animal, and cell culture models. Analysis of sub-proteomes
Aman P Mann et al.
Nature communications, 7, 11980-11980 (2016-06-29)
Traumatic brain injury (TBI) is a major health and socio-economic problem, but no pharmacological agent is currently approved for the treatment of acute TBI. Thus, there is a great need for advances in this field. Here, we describe a short
Arie C van Vliet et al.
Journal of neuropathology and experimental neurology, 74(9), 901-911 (2015-08-01)
Functional recovery does not occur in 10% of patients with neonatal brachial plexus palsy. In these patients, resection of a neuroma-in-continuity (NIC) and surgical nerve reconstruction are required. The formation of a NIC seems to prohibit functional recovery, but the
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service